ESK981

DRUG3 trials

Sponsors

Barbara Ann Karmanos Cancer Institute, University of Michigan Rogel Cancer Center

Conditions

Adenosquamous CarcinomaCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaGastrointestinal Neuroendocrine CarcinomaGastrointestinal Neuroendocrine TumorMetastatic Prostate CarcinomaNeuroendocrine Prostate CarcinomaPSA Progression

Phase 2

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

CompletedNCT03456804

Barbara Ann Karmanos Cancer InstituteCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma +2

Start: 2018-03-08End: 2023-05-09Updated: 2023-07-14

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

TerminatedNCT03562507

University of Michigan Rogel Cancer CenterRenal Cell Carcinoma, Metastatic

Start: 2019-04-11End: 2022-10-18Updated: 2024-05-20

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Active, not recruitingNCT05988918

University of Michigan Rogel Cancer CenterAdenosquamous Carcinoma, Gastrointestinal Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor +4

Start: 2024-04-19End: 2027-08-01Updated: 2026-05-14

Related Papers

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.

2024-09-03